Drug analysis: Tasigna

  • ID: 4462159
  • Drug Pipelines
  • 17 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division. The binding of Tasigna to the BCR-ABL protein blocks the signal that leads to the production of leukemic cells.

Novartis will continue to look to Tasigna to make up for Gleevec’s (imatinib; Novartis) downturn caused by the entry of generic imatinib into the chronic myeloid leukemia (CML) market. The second-generation tyrosine kinase inhibitor (TKI) has displayed cytogenetic and molecular response rates superior to those of Gleevec, but is likely to see its use remain primarily in the second-line setting alongside direct competitor Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka).
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Tasigna: Chronic myeloid leukemia (CML)

List of Figures
Figure 1: Tasigna for CML - SWOT analysis
Figure 2: Drug assessment summary of Tasigna for CML
Figure 3: Drug assessment summary of Tasigna for CML

List of Tables
Table 1: Tasigna drug profile
Table 2: Tasigna pivotal trial data in CML
Table 3: Tasigna late-phase trial data in CML
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll